Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis

By C. Chesnut, A. Skag, C. Christiansen, R. Recker, J. Stakkestad, A. Høiseth, D. Felsenberg, H. Huss, J. Gilbride, R. Schimmer and 1 more. Journal of Bone and Mineral Research, 2004

1,280 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/5cd4b6ea39f42b0dbaa46354856878dba6dcb6b8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Orthopedics and Sports Medicine

Citations in the corpus

European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, neutral): “5 mg [179] Vertebral fractures and LS −5<T-score≤−2.”
The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “Drug efficacy Ibandronate reduces incidence of vertebral fractures by about 33–50% over 3 years but does not reduce risk of non-vertebral fracture (hip/nonhip) [157].”
Bisphosphonates: the first 40 years. (2011, background): “then, risedronate [209,210], ibandronate [211], and most recently zoledronate [212].”
An overview and management of osteoporosis. (2017, background): “Ibandronate has been studied in trials of up to 3 years and its efficacy and safety beyond 3 years is not known (43).”
Denosumab and bisphosphonates: different mechanisms of action and effects. (2011, background): “In randomized controlled trials in postmenopausal women with osteoporosis, bisphosphonates have significantly reduced the risk of vertebral fractures by 39–70% compared with placebo [101,153–159].”
UK clinical guideline for the prevention and treatment of osteoporosis (2017, background): “0), a significant reduction in non-vertebral fractures was shown [76].”
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, background): “For radiographic vertebral fractures, RCTs with alendronate show a significant effect at 24 months (earlier time points have not been reported) [17]; ibandronate also had a significant effect at 24 months (although X-rays were done at 12 months, the effect at that time point was not statistically si”